Author/Authors :
Milanowski, Janusz Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland , Krukowska, Kinga Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland , Kieszko, Robert Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland , Kurek, Katarzyna Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland , Chmielewska, Izabela Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland , Krawczyk, Paweł Department of Pneumonology - Oncology and Allergology - Medical University of Lublin, Poland
Abstract :
Immunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. Inaddition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities thathave not been seen in patients receiving chemotherapy. In this article, we present a case of a patient with advanced lungadenocarcinoma who developed an EDTA-dependent pseudothrombocytopenia (PTCP) during pembrolizumab therapy. To thebest of our knowledge, this is thefirst reported case of EDTA-dependent PTCP occurring during immunotherapy treatment ofnonsmall lung cell cancer with ICI. The phenomenon of EDTA-dependent PTCP may prompt clinical decisions, as unnecessarytransfusions or even exclusion from pembrolizumab therapy. Therefore, it is important to be aware of PTCP as a possible sideeffect of this therapy
Keywords :
Pseudothrombocytopenia , during Pembrolizumab Therapy , NSCLC Patient , ICI , EDTA-dependent PTCP
